My watch list
my.bionity.com  
Login  

NovAliX enters into cooperation agreement with Max-Planck spin-off

28-Mar-2018

NovAliX, a drug discovery-focused Contract Research Organization (CRO) announces that it has signed a cooperation agreement with German-based ProteoPlex GmbH, a spin-off company of the Max-Planck-Institute for Biophysical Chemistry (MPIBPC). Under the terms of the agreement, NovAliX will exclusively offer to pharmaceutical companies purified human 20S proteasome as well as structural biology analysis by X-ray crystallography of the protein complex.

Proteasomes are promising targets for cancer drug development, including multiple myeloma, as well as for hematological malignancies. Proteasomes are cellular waste disposal units. Cancer cells heavily rely on them to dispose of their large amounts of waste. If this waste disposal is inhibited, apoptotic cell death ensues.

ProteoPlex itself has exclusive access to Max-Planck patents and know-how concerning the optimized production, purification and crystallization of high-grade proteins. For the 20S proteasome, these novel crystal structures could enable the discovery of improved chemical mechanisms for the inhibition of this proteasome.

According to the agreement, NovAliX will initially have exclusive access to these ultra-high-quality 20S proteasomes and to other clinically relevant protein structures in the future.

“We are delighted that, thanks to our cooperation with ProteoPlex, we can strengthen our expertise in structural biology and we can offer these high-quality proteasomes to the pharmaceutical industry for oncology research,” said Denis Zeyer, chief executive officer of NovAliX. “We have a well-established relationship with the Max-Planck-Institute for Biophysical Chemistry thanks to our cooperation in the field of cryo-electron microscopy. We are delighted to be extending that partnership.”

“NovAliX is a perfect partner for us to translate the results of Max-Planck's basic research into market-relevant products,” said Joerg Wamser, co-founder and managing director of ProteoPlex GmbH.
Proteasomes have an enormous potential market; for example the global multiple myeloma market is expected to reach $37.5 billion (€30.3bn) by 2024.

Facts, background information, dossiers
More about NovAliX
  • News

    NovAliX enters into fragment-based drug discovery alliance with Kyowa Hakko Kirin

    NovAliX SAS announced that it has entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin Co., Ltd., Japan. Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets. Under the terms of the agreement ... more

    NovAliX Names Dr Luc Van Hijfte as CSO Drug Discovery

    NovAliX  has announced that it has appointed pharma research executive Dr Luc Van Hijfte as CSO Drug Discovery.Dr. Van Hijfte brings a wealth of experience in pharmaceutical research with over 25 years spent in drug discovery. He joined from Janssen, a J&J company, where he served as Head o ... more

    NovAliX Enters into Multi-Target Integrated Drug Discovery Collaboration with Teijin Pharma

    NovAliX SAS announced that it has entered into a multi-target integrated drug discovery collaboration with Teijin Pharma Limited of Tokyo, Japan.Within the alliance the companies will collaborate to develop novel drug candidates against multiple targets across different therapeutic areas. N ... more

  • Companies

    NovAliX

    Strasbourg, France based NovAliX Group is focusing on the development of enabling chemistry and biophysical technologies to support the pharmaceutical industry’s outsourcing needs from discovery to manufacturing. With X-ray protein crystallography, supramolecular mass spectrometry and organ ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE